1.
Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials
by Ruff, Christian T, Dr
The Lancet (British edition), 2014, Vol.383 (9921), p.955-962
2.
Stroke prevention in atrial fibrillation
by Freedman, Ben, Prof
The Lancet (British edition), 2016, Vol.388 (10046), p.806-817
3.
2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer
by Farge, Dominique, MD
The lancet oncology, 2019, Vol.20 (10), p.e566-e581
4.
Deep vein thrombosis and pulmonary embolism
by Di Nisio, Marcello, Dr
The Lancet (British edition), 2016, Vol.388 (10063), p.3060-3073
5.
International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer
by Farge, Dominique, Prof
The lancet oncology, 2016, Vol.17 (10), p.e452-e466
6.
Erratum to “Non-vitamin K antagonist oral anticoagulant reversal: hope is on the horizon” [The American Journal of Surgery 212 (1) 160-164]
by Yorkgitis, Brian K., D.O
The American journal of surgery, 2016, Vol.212 (3), p.557-557
7.
The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study
by Hijazi, Ziad, Dr
The Lancet (British edition), 2016, Vol.387 (10035), p.2302-2311
8.
Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of...
by Wallentin, Lars, Prof
The Lancet (British edition), 2010, Vol.376 (9745), p.975-983
9.
Self-monitoring of oral anticoagulation: systematic review and meta-analysis of individual patient data
by Heneghan, Carl, Dr
The Lancet (British edition), 2012, Vol.379 (9813), p.322-334
10.
New oral anticoagulants and digestive endoscopy/Nouveaux anticoagulants oraux et endoscopie digestive
by Boustiere, C
Acta endoscopica, 2016, Vol.46 (5), p.308
11.
Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-b...
by Glund, Stephan, Dr
The Lancet (British edition), 2015, Vol.386 (9994), p.680-690
12.
Long-term outcome after additional catheter-directed thrombolysis versus standard treatment for acute iliofemoral deep vein thrombosis (the CaVenT study): a randomised controlled t...
by Enden, Tone, MD
The Lancet (British edition), 2012, Vol.379 (9810), p.31-38
13.
The future of atrial fibrillation management: integrated care and stratified therapy
by Kirchhof, Paulus, Prof
The Lancet (British edition), 2017, Vol.390 (10105), p.1873-1887
14.
New Oral Anticoagulants
by Wilbanks, Sandy
Journal for nurse practitioners, 2015, Vol.11 (9), p.928-928
15.
Meta-Analysis of Efficacy and Safety of New Oral Anticoagulants ( Dabigatran , Rivaroxaban , Apixaban ) Versus Warfarin in Patients With Atrial Fibrillation
by Miller, Corey S., BA
The American journal of cardiology, 2012, Vol.110 (3), p.453-460
16.
Corrigendum to "Unfractionated heparin attenuates LPS-induced IL-8 secretion via PI3K/Akt/NF-[kappa]B signaling pathway in human endothelial cells" [Immunobiology 220 399-405]
by Li, Xu
Immunobiology (1979), 2015, Vol.220 (10), p.1197
17.
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial
by Turpie, Alexander GG, MD
The Lancet (British edition), 2009, Vol.373 (9676), p.1673-1680
18.
A multifaceted intervention to improve treatment with oral anticoagulants in atrial fibrillation (IMPACT-AF): an international, cluster-randomised trial
by Vinereanu, Dragos
The Lancet (British edition), 2017, Vol.390 (10104), p.1737-1746
19.
Low-molecular-weight heparin and recurrent placenta-mediated pregnancy complications: a meta-analysis of individual patient data from randomised controlled trials
by Rodger, Marc A, Prof
The Lancet (British edition), 2016, Vol.388 (10060), p.2629-2641
20.
Bivalirudin versus heparin in patients planned for percutaneous coronary intervention: a meta-analysis of randomised controlled trials
by Cavender, Matthew A, MD
The Lancet (British edition), 2014, Vol.384 (9943), p.599-606
